Discover how T-cell receptor clonotype biomarkers help identify high-risk MF/SS patients, improving risk stratification and ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

According to one of the authors, additional work is needed to validate findings in a larger prospective study ‘and to apply ...

Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function NCOA3 expression was assessed using ...

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic ...

Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...